Citrullinemia is an autosomal recessive disorder caused by the deficiency of argininosuccinate synthetase (AS). It is characterized by elevated levels of blood citrulline and ammonia, which often results in hyperammonemic coma and early neonatal death in affected children. We have explored the use of adenoviral vectors as a treatment modality in a murine model of citrullinemia, the Ass mouse. The Ass mouse has no endogenous AS activity due to a targeted interruption of the AS gene. Homozygous mutant animals develop high levels of blood citrulline, become hyperammonemic, and die within 24-48 h after birth. We demonstrated that the neonatal crisis in Ass mice can be ameliorated by the injection of a recombinant adenovirus carrying human AS cDNA (Ad.CMVhAS) within hours after birth. The average life span of the virus-treated animals was extended from 30 ± 9.5 h to 16.1 ± 1.6 days. A second viral infusion 14 days after the first dose further prolonged the life span to an average of 36.2 ± 7.0 days, and to 40.7 ± 3.3 days with a concurrent daily injection of arginine and sodium
Introduction
A deficiency of AS (citrullinemia), the third enzyme in the urea cycle is inherited as an autosomal recessive trait. 1 The prevalence has been estimated as approximately one in 100 000. 2 A complete deficiency of this enzyme results in an interruption in the urea cycle and the inability to dispose of excess nitrogen derived from the metabolism of protein which lead to citrullinemia and hyperammonemic coma in the first week of life. The treatment for this disorder has been dietary restriction of protein combined with medications stimulating alternative pathways for excretion of excess nitrogen, or liver transplantation. However, newborn babies sustaining coma for more than 3 days usually suffer irreversible brain damage and resultant mental retardation and other developmental disabilities.
benzoate. Significantly increased liver AS activity (47.3 ± 7.9% of normal) was detected 24 h after viral infusion, which reached peak levels (80-90% of normal) at day 7 and decreased to about 20% of normal within 2-3 weeks after viral infusion. Southern blot analysis of liver DNA revealed a transduction efficiency of about one viral genome per hepatocyte 7 days after viral infusion and a gradual decrease of viral genome per cell parallel to the loss of liver AS activity. Plasma glutamine levels were partially normalized in virus-treated animals and were completely normalized in animals receiving Ad.CMVhAS concurrently with alternative pathway therapy. Plasma arginine levels were also partially normalized. Together, these results demonstrated that the recombinant adenovirus was capable of conferring AS activity in the liver of the recipient animals within 24 h, and the neonatal crisis of hyperammonemia could be averted by acute treatment with the AS containing adenovirus. Gene Therapy (2000) 7, 1777-1782. deficient gene in the target organ. This approach could be used for chronic maintenance therapy and/or as an acute treatment during neonatal crises. Recently, recombinant adenoviruses carrying wild-type AS gene have been tested in two animal models of citrullinemia.
The bovine model of citrullinemia was first reported by Harper et al 4 in dairy cattle in Australia. The affected animals have liver AS mRNA levels at less than 5% of controls due to a single base pair mutation. 5 Neonatal citrullinemic calves experience hyperammonemia and die within 24-48 h after birth without alternative pathway treatment. On this medication, they can be maintained for 1-2 weeks but often with steady decline in clinical status as judged by poor feeding, characteristic head pressing, and decreased level of activity. It has been recently reported that the systemic administration of an E1-deleted adenoviral vector expressing human AS resulted in transduction of hepatocytes and partial correction of the enzyme defect. There was significant restoration of urea synthesis and the calves showed clinical improvement and normalization of plasma glutamine levels. 6 The murine model of citrullinemia, the Ass mouse, was generated by Patejunas et al 7 in 1994 by targeted disruption of the argininosuccinate synthetase gene. Homozygous mutant animals develop high levels of plasma citrulline, become hyperammonemic, and die within 24-48 h after birth. The phenotype of the mutant mice closely resembles that of humans with AS deficiency. The life span of homozygous animals can be extended to 4-6 days by a dietary treatment regimen using a combination of arginine and sodium benzoate. The animals, however, do not gain any weight during this period of time. Patejunas et al have tried to treat the Ass mice with an E1-deleted recombinant adenovirus carrying a human AS cDNA under the control of the RNA polymerase II promoter. 8 Introduction of the adenoviral vector to heterozygous or homozygous normal animals did not result in any detrimental effects. In a single homozygous Ass mouse, a partial correction of citrullinemia was accomplished as evidenced by an extended life span, from 4-6 days to 11 days, with concurrent dietary treatment. However, it was not clear whether the extended life span was a result of virus-mediated AS expression or the concurrent treatment. The lack of weight gain in this mouse during its life span suggested that nutritional status remained suboptimal.
In this study, we have attempted to restore liver AS activity in newborn Ass homozygote mice with an E1-deleted recombinant adenovirus carrying human AS cDNA under the control of a CMV promoter.
Results
Neonatal injection of Ad.CMVhAS prolonged the life span of homozygous Ass mice We hypothesized that a recombinant adenovirus injected into neonatal Ass mice would express the therapeutic gene (AS) within 24 h and at a level high enough to avert the citrullinemia/hyperammonemia in affected animals. Newborn pups from heterozygote × heterozygote matings were injected retro-orbitally with Ad.CMVhAS at various doses within 8 h of birth. The genotype of surviving animals was determined by PCR analysis of tail DNA at day 4 after birth. It was found that a viral dose of 3 × 10 9 particles per mouse could significantly prolong the life span of Ass homozygotes from 30 ± 9.5 h to 84 ± 16.8 h; this was further extended to an average of 16 days with higher viral doses (2 × 10 10 particles per mouse). However, significant viral toxicity was observed at doses higher than 2 × 10 10 particles per mouse, as evidenced by increased overall mortality of injected neonates. Injection of a non-AS containing virus (Ad.CMVlacZ) at any dose showed no effect on the life span of Ass/Ass mice ( Figure 1) .
A second viral infusion combined with alternative pathway therapy led to further improved life span of Ass homozygotes Although an infusion of recombinant adenovirus into an adult immune-competent mouse usually leads to the development of neutralizing antibodies, 9,10 which would prevent virus entry to cells in subsequent infections, we have observed in earlier studies that intravenous injections of recombinant adenovirus in newborn mice (within 48 h after birth) do not seem to result in host immune responses to either viral vector or the transgene product (unpublished observation). We therefore reasoned that a second infusion of recombinant adenovirus in neonatally injected Ass mice should result in effective transgene expression. To test this hypothesis, neonatally injected Ass mice were treated with a second dose of Ad.CMVhAS at day 14 after birth. The second injection of virus effectively extended the life span of these animals from 16.1 ± 1.6 days to 36.2 ± 7.0 days ( Figure 2) . A third injection of the virus at day 30 after birth, however, did not result in any improvement in life span of these animals (data not shown). Analysis of plasma from mice receiving single (day 0) or double (days 0, 14) viral injections revealed the development of anti-adenovirus neutralizing antibodies after the second viral dose (Table 1) .
Histological examination of virus-treated Ass homozygotes at different times after birth revealed normal body and organ development in these animals. The animals usually showed normal behavior until a few days before death, when they became dormant and experienced rapid weight loss. However, virus-treated Ass homozygotes lagged behind their normal and heterozygous littermates in both body weight ( Figure 3a ) and fur development (Figure 3b ), an indication of arginine deficiency. It therefore appeared that the virus-mediated AS expression in the liver did not completely correct the metabolic deficiencies in these animals. To improve their ammonium metabolism and to compensate for arginine deficiency, a group of homozygous Ass mice were treated with daily intraperitoneal injections of sodium benzoate (0.1 g/kg) and arginine (1 g/kg) starting at day 3 after birth, concurrently with intravenous injections of Ad.CMVhAS at days 0 and 14. This alternative pathway therapy appeared to have a mild effect on the growth Single injection (day 0) ND (n = 6) --Double injection (days 0, ND (n = 4) 20-40 (n = 4) 40-80 (n = 4) 14)
Newborn Ass homozygotes were injected with Ad.CMVhAS at day 0 (3 × 10 10 particles per mouse) or at days 0 and 14 (3 × 10 10 and 1.5 × 10 11 particles per mouse, respectively) after birth. Plasma samples were taken at the indicated time-points and analyzed for anti-adenovirus neutralizing antibody activity as described in Materials and methods. ND, not detectable. curve (Figure 3) , and the average life span of these animals by another 4 days (from 36.2 ± 7.0 to 40.7 ± 3.3 days (Figure 2) . However, statistical analysis showed no significant difference between the double-dose and doubledose + APT groups.
Injection of Ad.CMVhAS resulted in increased liver AS activity and improved plasma amino acid profile in Ass homozygotes To confirm that the injection of Ad.CMVhAS led to functional AS expression in the liver of recipient animals, virus-treated Ass homozygotes were killed at different time-points after viral injection. Their liver tissues were harvested and analyzed for AS activity. As shown in Figure 4a , liver AS activity was significantly increased to 49% of normal 24 h after viral injection, and reached 74% or 100% of normal 7 days after the first or second viral infusion, respectively. The AS activity decreased to about 20% of normal within 2 weeks of the first viral infusion and within 3 weeks of the second infusion. Southern blot analysis of liver DNA revealed a transduction efficiency of about one viral genome per hepatocyte 7 days after viral infusion and a gradual dilution or loss of viral genome parallel to the loss of liver AS activity (Figure 4b) . Plasma amino acid analysis of the virus-treated animals demonstrated completely normalized glutamine levels, a marker for nitrogen accumulation (Figure 5a ). The citrulline levels were not normalized by the virus treatment alone, but were significantly reduced by concurrent alternative pathway therapy (Figure 5b ). The arginine levels were significantly increased to near normal levels by the virus treatment (Figure 5c ). In contrast to an earlier observation, no significant changes in plasma alanine levels (another marker of nitrogen accumulation) were observed in Ass mice, nor did the virus or virus/ alternative pathway treatment affect the alanine levels (data not shown).
Discussion
Recombinant adenoviral vectors are powerful tools for effective gene transfer to a variety of tissues in vivo. However, there are considerable immunological problems to be overcome before these vectors can be used to produce sustained expression of delivered genes. On the other hand, adenoviral vectors are extremely useful if expression of the transgene is required at high levels for short periods of time. One of the possible applications is to use adenoviral vectors to restore quickly a missing enzyme function, such as liver AS activity in citrullinemic patients who are in neonatal hyperammonemic coma. We demonstrated in this study that liver AS activity in Ass mice could be restored to Ͼ40% of normal within 24 h after the retro-orbital injection of Ad.CMVhAS, and that the viral treatment effectively prevented the development of neonatal crisis in the affected animals. This finding, combined with our earlier observation that ornithine transcarbamylase (OTC)-deficient mice were protected from an otherwise lethal ammonium challenge by an injection of OTC containing adenoviruses 24 h before the challenge, 11 suggests that adenovirus-mediated transgene expression may be rapid enough to permit effective treatment of hyperammonemic coma. The therapeutic gene expression in the liver, however, will likely to be diluted significantly due to the rapid growth during the neonatal period, as demonstrated by the decrease of liver AS activity and viral genomes per cell in virus-treated Ass mice following neonatal injection. Repeated viral administrations may become necessary in order to maintain normal AS activity in the liver.
It was not surprising that a second infusion of the same virus resulted in effective gene transfer and further prolonged life span of neonatally injected Ass mice. We observed in an earlier study (unpublished observation) that virus given in the neonatal period appeared to be ignored by the host immune system, ie there was no indication of cellular or humoral immune responses to the virus in these animals. However, these animals were not tolerant to the viral vector; a second viral infusion at an older age resulted in both cellular and humoral immune responses to the adenovirus. Our data from Ass mice receiving two doses of Ad.CMVhAS indicated that all animals developed neutralizing antibodies to adenovirus after the second viral infusion, which rendered the third viral injection ineffective. The first two successful viral administrations extended the average life span of Ass homozygotes from 1 day to 36 days. It therefore provided a window for the use of other types of treatment that may confer a sustained effect, such as alternative pathway therapy or potentially gene transfer with adenoassociated virus (AAV) vectors.
The slower growth and lack of fur in virus-treated Ass homozygotes in comparison with their wild-type or heterozygous littermates suggests that the metabolic/nutritional status of these animals was not completely normalized. The slower growth of virustreated homozygous Ass mice was not a result of viral toxicity or insufficient food intake, since every pup in each litter received the same dose of virus and the litter size was reduced to three after genotyping to allow equal access to the dam. Moreover, the affected animals always had milk in their stomachs during the first 2 weeks of life when the observation could be made. It therefore suggested that reconstitution of liver AS activity alone may not be sufficient to restore completely normal protein metabolism in these animals. It is known that kidney is also involved in citrulline clearance and arginine synthesis 12 and those functions were not restored by virusmediated AS expression in the liver. The plasma amino acids profile of virus-treated animals clearly indicated that the citrulline level was not normalized by the treat- ment. Similar observations have been made in citrullinemia patients receiving liver transplantation that their citrulline levels remain elevated after transplantation. 13 Although the citrullinemia in Ad.CMVhAS-treated Ass mice can be partially corrected by concurrent alternative pathway treatment, there was only a marginal improvement on their life span (from 36.2 ± 7.0 to 40.7 ± 3.3 days). This result, combined with our observation that liver AS activity decreased to less than 20% of normal during the last week of life in the virus-treated animals, suggested that the level of virus-mediated AS expression in the liver was the key factor that determined the survival of Ass mice. When virus-mediated AS expression falls below a critical level needed to maintain minimal ammonium metabolism, alternative pathway therapy alone would not be able to further prolong the life span of these animals. It is still not clear why the injection of arginine and sodium benzoate led to reduced citrulline levels in Ad.CMVhAS-treated Ass mice. In citrullinemia patients receiving arginine therapy, plasma and urine citrulline concentrations rise markedly, therefore creating an alternative pathway for nitrogen excretion. 14 The effect of alternative pathway therapy in mice has not yet been fully explored.
Materials and methods
Mice and recombinant adenovirus Homozygous Ass mice were produced by a heterozygote x heterozygote mating at the animal facility in Children's National Medical Center. The human AS cDNA was obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and cloned into an adenovirus shuttle vector pAd.CMV-link1. The resulting plasmid, designated pAd.CMVhAS, was cotransfected into 293 cells with ClaI-digested adenovirus DNA (sub360). The resulting virus (Ad.CMVhAS) was purified through three rounds of plaque isolation. The recombinant adenovirus containing ␤-galactosidase gene (Ad.CMVlacZ) was constructed as described. 11 Newborn Ass mice were injected retro-orbitally with 20 l of Ad.CMVhAS or AdCMVlacZ suspended in phosphate-buffered saline (PBS) within 8 h Gene Therapy after birth. Animals under concurrent alternative pathway therapy received a daily i.p. injection of arginine (1 g/kg) and sodium benzoate (0.1 g/kg) starting at day 3 after birth.
Determination of plasma amino acids
Plasma amino acids were analyzed by precolumn derivitization with o-phthaldialdehyde as previously described. 15 After centrifugation of heparinized blood, an aliquot of plasma was immediately precipitated with an equal volume of 0.8 n perchloric acid which contained the internal standards L-␣-aminoadipate and L-␣-aminon-butyric acid. After centrifugation, an aliquot of the supernatants was neutralized with 2 m KHCO 3 . These samples were derivitized using an autosampler. External standards were injected after every fifth specimen.
AS radiochemical assay Argininosuccinate synthetase activity was determined using a method based on the conversion of 14 C-aspartate to 14 C-argininosuccinate. 16 Reactions contained 5 mm citrulline, 10 mm Tris-HCl, pH 7.5, 1 mm ATP, 5 mm MgCl 2 , 20 mm KCl, 2 mm phosphoenolpyruvate, 20 U/ml pyruvate kinase, 1.7 g/ml pyrophosphatase, 8.3 U/ml myokinase, and 1 mm 14 C-aspartic acid (1000 d.p.m./ nmol) in a total volume of 0.3 ml. Reactions were incubated at 37°C for 1 h and were terminated by the addition of 0.7 ml ice-cold H 2 O. The mixture was applied to 0.4 × 4 cm columns of Dowex 1-X8 acetate equilibrated with 10 mm Tris-acetate, pH 7.4. Two 1-ml volumes of the same buffer were used to rinse the reaction tubes and were also applied to the column. The effluent was discarded, and argininosuccinate was eluted with 4 ml of 0.05 m HOAc. A 1-ml aliquot of the effluent was removed for scintillation counting.
Genotyping of Ass mice
Genotypes of Ass mice were determined by a PCR assay using tail DNA. Two sets of primers were used. Primers oIMR142 and oIMR143 amplified a 145 bp band from the Ass wild-type allele with exon 4. Primers oIMR143 and oIMR144 amplified a 300 bp band from the Ass mutant allele from within the bovine growth hormone polyA sequences of the targeting construct to the exon 4 sequences 3′ of the neo insertion. PCR conditions were: 2.5 mm MgCl 2 , 0.2 mm dNTPs, 0.025 U/l Taq ploymerase, 1 m of each primer, 100 ng target DNA, total reaction volume 25 l. Cycling conditions were: 95°C 30 s, 55°C 30 s, 72°C 1 min, 30-35 cycles. Primer sequences were: oIMR142: 5′-CTGGGGCCTCACGATTCT-3′; Pimr143: 5′-GACCTTCTCATCGTCTTACCTTT-3′; oIMR144: 5′-CCTTCTAGTTGCCAGCCATC-3′.
Determination of anti-adenovirus neutralizing antibody titer
To determine the neutralizing antibody activity, plasma samples were diluted in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS) in two-fold steps starting from 1:10. Each antibody dilution (100 l) was mixed with 100 l of DMEM containing 10% FBS and 1 × 10 5 p.f.u. of Ad.CBlacZ, incubated for 1 h at 37°C, and applied to 80% confluent HeLa cells in 96-well plates. The cells were incubated at 37°C for 24 h, fixed in 0.5% glutaraldehyde at room temperature for 10 min, washed with PBS, and stained for 2 h at 37°C in PBS containing 5 mm K 3 Fe(CN) 6 , 5 mm K 4 Fe(CN) 6 , 1 mm MgCl 2 , and 1 mg/ml 5-bromo-4-chloro-3-indolyl-␤-d-galactopyranoside (X-gal). The titer of neutralizing antibodies was defined as the highest dilution at which less than 50% of the cells stained positive for lacZ. A protein A column purified mouse anti-adenovirus neutralizing antibody was used in the experiments as a standard. The purified antibody (1 mg/ml) had a neutralizing titer of 3200. The sensitivity of the assay was 0.2 ± 0.1 g/ml using the purified neutralizing antibody. The assay was linear within a range of 0.1-2 g/ml using the same antibody.
Liver DNA extraction and Southern blot analysis Total liver DNA was extracted with a Qiagen Genomic DNA Kit (Qiagen, Valencia, CA, USA). Ten micrograms of DNA from each sample were digested with HindIII, fractionated on an agarose gel, and transferred to a Hybond nylon filter (Amersham Pharmacia, Piscataway, NJ, USA). Control samples contained liver DNA from uninfected animals spiked with known quantities of adenovirus DNA at an equivalent of one or 10 virus copies per cell. DNA fragments used as probes in the Southern blot were gel-purified and labeled with ␣-32 P dCTP by random priming.
Statistical analysis
The survivor functions for the virus-treated Ass/Ass mice were estimated using the Kaplan-Meier method, the equality of the curves were then tested by way of the Wilcoxon 2 test. A repeated measures analysis of variance was used to test the difference in weights of the pups by dose level over time. Dose levels were considered a between pup factor with five levels for the different doses (+/+ and Ass/+ groups and three Ass/Ass groups treated with single-dose, double-dose, and double-dose + APT). Each pup was considered random and nested within dose group.
